The paraoxonase gene family and atherosclerosis

Free Radical Biology and Medicine

Volumn 38, Issue 2, 2005, Pages 153-163

  Ng, Carey J ^a   Shih, Diana M ^a   Hama, Susan Y ^a   Villa, Natividad ^a   Navab, Mohamad ^a   Reddy, Srinivasa T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Free radicals; HDL function; LDL oxidation; Lipoprotein metabolism; Paraoxonases

Indexed keywords

ARYLDIALKYLPHOSPHATASE; FREE RADICAL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; DOWN REGULATION; ENZYME ACTIVITY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; KNOCKOUT MOUSE; LIPOPROTEIN METABOLISM; MULTIGENE FAMILY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; DOWN-REGULATION; FEMALE; FREE RADICALS; GENOTYPE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIGENE FAMILY; OXIDATIVE STRESS; OXYGEN; POLYMORPHISM, GENETIC; UP-REGULATION;

MUS MUSCULUS;

EID: 10644244414     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.09.035     Document Type: Review

References (102)

1. W.P. Castelli, R.J. Garrison, P.W. Wilson, R.D. Abbott, S. Kalousdian, and W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study JAMA 256 1986 2835 2838
2. G.J. Miller, and N.E. Miller Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease Lancet 1 1975 16 19
3. N.E. Miller, D.S. Thelle, O.H. Forde, and O.D. Mjos The Tromso heart-study: high-density lipoprotein and coronary heart-disease: a prospective case-control study Lancet 1 1977 965 968
4. W.P. Castelli Lipids, risk factors and ischaemic heart disease Atherosclerosis 124 1996 S1 S9 [Suppl.]
5. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, J.D. Knoke, D.R. Jacobs Jr., S. Bangdiwala, and H.A. Tyroler High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15
6. M. Navab, G.M. Ananthramaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, G.C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, J.A. Berliner, A.J. Lusis, and A.M. Fogelman Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J. Lipid Res. 45 2004 993 1007
7. M. Navab, S.Y. Hama, C.J. Cooke, G.M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K.F. Faull, S.T. Reddy, N.E. Miller, and A.M. Fogelman Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1 J Lipid Res. 41 2000 1481 1494
8. M. Navab, S.Y. Hama, G.M. Anantharamaiah, K. Hassan, G.P. Hough, A.D. Watson, S.T. Reddy, A. Sevanian, G.C. Fonarow, and A.M. Fogelman Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3 J. Lipid Res. 41 2000 1495 1508
9. L.G. Costa, and C.E. Furlong Paraoxonase (PON1) in health and disease: basic and clinical aspects 2002 Kluwer Academic Boston
10. S.L. Primo-Parmo, R.C. Sorenson, J. Teiber, and B.N. La Du The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family Genomics 33 1996 498 507
11. D.I. Draganov, and B.N. La Du Pharmacogenetics of paraoxonases: a brief review Naunyn Schmiedeberg's Arch. Pharmacol. 369 2004 78 88
12. S.T. Reddy, D.J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D.M. Shih, A.J. Lusis, M. Navab, and A.M. Fogelman Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids Arterioscler. Thromb. Vasc. Biol. 21 2001 542 547
13. C.J. Ng, D.J. Wadleigh, A. Gangopadhyay, S. Hama, V.R. Grijalva, M. Navab, A.M. Fogelman, and S.T. Reddy Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein J. Biol. Chem. 276 2001 44444 44449
14. C.E. Furlong, R.J. Richter, S.L. Seidel, L.G. Costa, and A.G. Motulsky Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase Anal. Biochem. 180 1989 242 247
15. C. Hassett, R.J. Richter, R. Humbert, C. Chapline, J.W. Crabb, C.J. Omiecinski, and C.E. Furlong Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence Biochemistry 30 1991 10141 10149
16. L.G. Costa, W.F. Li, R.J. Richter, D.M. Shih, A. Lusis, and C.E. Furlong The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism Chem. Biol. Interact. 119/120 1999 429 438
17. D.I. Draganov, P.L. Stetson, C.E. Watson, S.S. Billecke, and B.N. La Du Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation J. Biol. Chem. 275 2000 33435 33442
18. I. Leviev, and R.W. James Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations Arterioscler. Thromb. Vasc. Biol. 20 2000 516 521
19. R.W. James, I. Leviev, J. Ruiz, P. Passa, P. Froguel, and M.C. Garin Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients Diabetes 49 2000 1390 1393
20. V.H. Brophy, M.D. Hastings, J.B. Clendenning, R.J. Richter, G.P. Jarvik, and C.E. Furlong Polymorphisms in the human paraoxonase (PON1) promoter Pharmacogenetics 11 2001 77 84
21. V.H. Brophy, R.L. Jampsa, J.B. Clendenning, L.A. McKinstry, G.P. Jarvik, and C.E. Furlong Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression Am. J. Hum. Genet. 68 2001 1428 1436
22. H. Schmidt, R. Schmidt, K. Niederkorn, A. Gradert, M. Schumacher, N. Watzinger, H.P. Hartung, and G.M. Kostner Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study Stroke 29 1998 2043 2048
23. I. Leviev, F. Negro, and R.W. James Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism Arterioscler. Thromb. Vasc. Biol. 17 1997 2935 2939
24. B. Mackness, M.I. Mackness, S. Arrol, W. Turkie, and P.N. Durrington Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon Br. J. Pharmacol. 122 1997 265 268
25. S.N. Akhmedova, A.K. Yakimovsky, and E.I. Schwartz Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease J. Neurol. Sci. 184 2001 179 182
26. R. Malin, O. Jarvinen, T. Sisto, T. Koivula, and T. Lehtimaki Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis Atherosclerosis 157 2001 301 307
27. R. Malin, A. Loimaala, A. Nenonen, M. Mercuri, I. Vuori, M. Pasanen, P. Oja, G. Bond, T. Koivula, and T. Lehtimaki Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men Metabolism 50 2001 1095 1101
28. G. Fortunato, P. Rubba, S. Panico, D. Trono, N. Tinto, C. Mazzaccara, M. De Michele, A. Iannuzzi, D.F. Vitale, F. Salvatore, and L. Sacchetti A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women Atherosclerosis 167 2003 141 148
29. I. Leviev, S. Deakin, and R.W. James Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations J. Lipid Res. 42 2001 528 535
30. C.E. Furlong, T.B. Cole, G.P. Jarvik, and L.G. Costa Pharmacogenomic considerations of the paraoxonase polymorphisms Pharmacogenomics 3 2002 341 348
31. H.G. Davies, R.J. Richter, M. Keifer, C.A. Broomfield, J. Sowalla, and C.E. Furlong The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin Nat. Genet. 14 1996 334 336
32. L.G. Costa, T.B. Cole, G.P. Jarvik, and C.E. Furlong Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism Annu. Rev. Med. 54 2003 371 392
33. Y. Hu, H. Tian, and R. Liu Gln-Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese Diabetes Res. Clin. Pract. 61 2003 21 27
34. Q. Chen, S.E. Reis, C.M. Kammerer, D.M. McNamara, R. Holubkov, B.L. Sharaf, G. Sopko, D.F. Pauly, C.N. Merz, and M.I. Kamboh Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study Am. J. Hum. Genet. 72 2003 13 22
35. B. Voetsch, K.S. Benke, B.P. Damasceno, L.H. Siqueira, and J. Loscalzo Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults Stroke 33 6 2002 1459 1464
36. Y. Imai, H. Morita, H. Kurihara, T. Sugiyama, N. Kato, A. Ebihara, C. Hamada, Y. Kurihara, T. Shindo, Y. Oh-hashi, and Y. Yazaki Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases Atherosclerosis 149 2000 435 442
37. M. Pfohl, M. Koch, M.D. Enderle, R. Kuhn, J. Fullhase, K.R. Karsch, and H.U. Haring Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes Diabetes 48 1999 623 627
38. I. Kondo, and M. Yamamoto Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease Brain Res. 806 1998 271 273
39. R.A. Hegele, J.H. Brunt, and P.W. Connelly A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate Arterioscler. Thromb. Vasc. Biol. 15 1995 89 95
40. M. Odawara, Y. Tachi, and K. Yamashita Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 82 1997 2257 2260
41. M. Marchesani, A. Hakkarainen, T.P. Tuomainen, J. Kaikkonen, E. Pukkala, P. Uimari, E. Seppala, M. Matikainen, O.P. Kallioniemi, J. Schleutker, T. Lehtimaki, and J.T. Salonen New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men J. Natl. Cancer Inst. 95 2003 812 818
42. J.G. Wheeler, B.D. Keavney, H. Watkins, R. Collins, and J. Danesh Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies Lancet 363 2004 689 695
43. F. Azizi, F. Raiszadeh, M. Solati, A. Etemadi, M. Rahmani, and M. Arabi Serum paraoxonase 1 activity is decreased in thyroid dysfunction J. Endocrinol. Invest. 26 2003 703 709
44. M. Senti, M. Tomas, M. Fito, T. Weinbrenner, M.I. Covas, J. Sala, R. Masia, and J. Marrugat Antioxidant paraoxonase 1 activity in the metabolic syndrome J. Clin. Endocrinol. Metab. 88 2003 5422 5426
45. S. Biasioli, R. Schiavon, L. Petrosino, E. De Fanti, G. Cavalcanti, P. Battaglia, and A. Fasolin Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia Asaio J. 49 2003 295 299
46. N. Tanimoto, Y. Kumon, T. Suehiro, S. Ohkubo, Y. Ikeda, K. Nishiya, and K. Hashimoto Serum paraoxonase activity decreases in rheumatoid arthritis Life Sci. 72 2003 2877 2885
47. B. Mackness, P.N. Durrington, A.J. Boulton, D. Hine, and M.I. Mackness Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls Eur. J. Clin. Invest. 32 2002 259 264
48. B. MacKness, M.I. Mackness, P.N. Durrington, S. Arrol, A.E. Evans, D. McMaster, J. Ferrieres, J.B. Ruidavets, N.R. Williams, and A.N. Howard Paraoxonase activity in two healthy populations with differing rates of coronary heart disease Eur. J. Clin. Invest. 30 2000 4 10
49. T.F. Dantoine, J. Debord, J.P. Charmes, L. Merle, P. Marquet, G. Lachatre, and C. Leroux-Robert Decrease of serum paraoxonase activity in chronic renal failure J. Am. Soc. Nephrol. 9 1998 2082 2088
50. G. Paragh, I. Seres, Z. Balogh, Z. Varga, I. Karpati, J. Matyus, L. Ujhelyi, and G. Kakuk The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia Nephron. 80 1998 166 170
51. G.P. Jarvik, T.S. Hatsukami, C. Carlson, R.J. Richter, R. Jampsa, V.H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G.D. Schellenberg, P.J. Heagerty, and C.E. Furlong Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease Arterioscler. Thromb. Vasc. Biol. 23 2003 1465 1471
52. B. Mackness, G.K. Davies, W. Turkie, E. Lee, D.H. Roberts, E. Hill, C. Roberts, P.N. Durrington, and M.I. Mackness Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21 2001 1451 1457
53. G.P. Jarvik, L.S. Rozek, V.H. Brophy, T.S. Hatsukami, R.J. Richter, G.D. Schellenberg, and C.E. Furlong Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype Arterioscler. Thromb. Vasc. Biol. 20 2000 2441 2447
54. B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study Circulation 107 2003 2775 2779
55. R. Humbert, D.A. Adler, C.M. Disteche, C. Hassett, C.J. Omiecinski, and C.E. Furlong The molecular basis of the human serum paraoxonase activity polymorphism Nat. Genet. 3 1993 73 76
56. M. Navab, S. Hama-Levy, B.J. Van Lenten, G.C. Fonarow, C.J. Cardinez, L.W. Castellani, M.L. Brennan, A.J. Lusis, A.M. Fogelman, and B.N. La Du Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio J. Clin. Invest. 99 1997 2005 2019
57. B.J. Van Lenten, A.C. Wagner, M. Navab, and A.M. Fogelman Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6 J. Biol. Chem. 276 2001 1923 1929
58. Y. Kumon, T. Suehiro, Y. Ikeda, and K. Hashimoto Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6 Life Sci. 73 2003 2807 2815
59. S. Deakin, I. Leviev, S. Guernier, and R.W. James Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2 Arterioscler. Thromb. Vasc. Biol. 23 2003 2083 2089
60. K.R. Feingold, R.A. Memon, A.H. Moser, and C. Grunfeld Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response Atherosclerosis 139 1998 307 315
61. D.M. Shih, L. Gu, S. Hama, Y.R. Xia, M. Navab, A.M. Fogelman, and A.J. Lusis Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model J. Clin. Invest. 97 1996 1630 1639
62. N.M. de Roos, E.J. Schouten, L.M. Scheek, A. van Tol, and M.B. Katan Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women Metabolism 51 2002 1534 1537
63. M. Sent, M. Tomas, R. Anglada, R. Elosua, M.-I. Covas, and M. Fito Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study Eur. J. Intern. Med. 14 2003 178 184
64. A.J. Wallace, W.H. Sutherland, J.I. Mann, and S.M. Williams The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes Eur. J. Clin. Nutr. 55 2001 951 958
65. W.H. Sutherland, R.J. Walker, S.A. de Jong, A.M. van Rij, V. Phillips, and H.L. Walker Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat Arterioscler. Thromb. Vasc. Biol. 19 1999 1340 1347
66. G.P. Jarvik, N.T. Tsai, L.A. McKinstry, R. Wani, V.H. Brophy, R.J. Richter, G.D. Schellenberg, P.J. Heagerty, T.S. Hatsukami, and C.E. Furlong Vitamin C and E intake is associated with increased paraoxonase activity Arterioscler. Thromb. Vasc. Biol. 22 2002 1329 1333
67. M. Tomas, M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients Arterioscler. Thromb. Vasc. Biol. 20 2000 2113 2119
68. M.S. van der Gaag, A. van Tol, L.M. Scheek, R.W. James, R. Urgert, G. Schaafsma, and H.F. Hendriks Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men Atherosclerosis 147 1999 405 410
69. A. Sierksma, M.S. van der Gaag, A. van Tol, R.W. James, and H.F. Hendriks Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers Alcohol Clin. Exp. Res. 26 2002 1430 1435
70. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, and B.N. La Du Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase J. Clin. Invest. 101 1998 1581 1590
71. J.F. Teiber, D.I. Draganov, and B.N. La Du Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3 Biochem. Pharmacol. 66 2003 887 896
72. A.D. Watson, J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman, and M. Navab Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein J. Clin. Invest. 96 1995 2882 2891
73. L. Rodrigo, B. Mackness, P.N. Durrington, A. Hernandez, and M.I. Mackness Hydrolysis of platelet-activating factor by human serum paraoxonase Biochem. J. 354 Pt. 1 2001 1 7
74. O. Rozenberg, D.M. Shih, and M. Aviram Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation Arterioscler. Thromb. Vasc. Biol. 23 2003 461 467
75. G.K. Marathe, G.A. Zimmerman, and T.M. McIntyre Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles J. Biol. Chem. 278 2003 3937 3947
76. A. Fokine, R. Morales, C. Contreras-Martel, P. Carpentier, F. Renault, D. Rochu, and E. Chabriere Direct phasing at low resolution of a protein copurified with human paraoxonase (PON1) Acta. Crystallogr. D. 59 Pt. 12 2003 2083 2087
77. M. Harel, A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R.B. Ravelli, A. McCarthy, L. Toker, I. Silman, J.L. Sussman, and D.S. Tawfik Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes Nat. Struct. Mol. Biol. 11 2004 412 419
78. M.I. Mackness, S. Arrol, C. Abbott, and P.N. Durrington Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
79. M. Aviram, S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R Arterioscler. Thromb. Vasc. Biol. 18 1998 1617 1624
80. R.C. Sorenson, S.L. Primo-Parmo, C.L. Kuo, S. Adkins, O. Lockridge, and B.N. La Du Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase Proc. Natl. Acad. Sci. USA 92 1995 7187 7191
81. J.A. Doorn, R.C. Sorenson, S.S. Billecke, C. Hsu, and B.N. La Du Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase Chem. Biol. Interact. 119/120 1999 235 241
82. P.N. Durrington, B. Mackness, and M.I. Mackness Paraoxonase and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 21 2001 473 480
83. D.M. Shih, L. Gu, Y.R. Xia, M. Navab, W.F. Li, S. Hama, L.W. Castellani, C.E. Furlong, L.G. Costa, A.M. Fogelman, and A.J. Lusis Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 394 1998 284 287
84. D.M. Shih, Y.R. Xia, X.P. Wang, E. Miller, L.W. Castellani, G. Subbanagounder, H. Cheroutre, K.F. Faull, J.A. Berliner, J.L. Witztum, and A.J. Lusis Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis J. Biol. Chem. 275 2000 17527 17535
85. M.N. Oda, J.K. Bielicki, T.T. Ho, T. Berger, E.M. Rubin, and T.M. Forte Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins Biochem. Biophys. Res. Commun. 290 2002 921 927
86. A. Tward, Y.R. Xia, X.P. Wang, Y.S. Shi, C. Park, L.W. Castellani, A.J. Lusis, and D.M. Shih Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice Circulation 106 2002 484 490
87. R.A. Hegele, S.B. Harris, P.W. Connelly, A.J. Hanley, L.C. Tsui, B. Zinman, and S.W. Scherer Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree Clin. Genet. 54 1998 394 399
88. R.A. Hegele, P.W. Connelly, S.W. Scherer, A.J. Hanley, S.B. Harris, L.C. Tsui, and B. Zinman Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 82 1997 3373 3377
89. R.A. Hegele Paraoxonase genes and disease Ann. Med. 31 1999 217 224
90. J. Shi, S. Zhang, M. Tang, X. Liu, T. Li, H. Han, Y. Wang, Y. Guo, J. Zhao, H. Li, and C. Ma Possible association between Cys311Ser polymorphism of paraoxonase 2 gene and late-onset Alzheimer's disease in Chinese Brain Res. Mol. Brain Res. 120 2004 201 204
91. X.Y. Wang, Y.M. Xue, S.J. Wen, N.L. Zhang, Z. Ji, and S.Y. Pan The association of paraoxonase 2 gene C311S variant with ischemic stroke in Chinese type 2 diabetes mellitus patients Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20 2003 215 219
92. J.P. Pan, S.T. Lai, S.C. Chiang, S.C. Chou, and A.N. Chiang The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene Zhonghua Yi Xue Za Zhi (Taipei) 65 2002 415 421
93. Y. Kao, K.C. Donaghue, A. Chan, B.H. Bennetts, J. Knight, and M. Silink Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes Diabet. Med. 19 2002 212 215
94. Z. Janka, A. Juhasz, A.A. Rimanoczy, K. Boda, J. Marki-Zay, and J. Kalman Codon 311 (Cys→Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias Mol. Psychiatry. 7 2002 110 112
95. D.K. Sanghera, C.E. Aston, N. Saha, and M.I. Kamboh DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease Am. J. Hum. Genet. 62 1998 36 44
96. N. Martinelli, D. Girelli, O. Olivieri, C. Stranieri, E. Trabetti, F. Pizzolo, S. Friso, I. Tenuti, S. Cheng, M.A. Grow, P.F. Pignatti, and R. Corrocher Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction Eur. J. Clin. Invest. 34 2004 14 20
97. Y. Yamada, F. Ando, N. Niino, T. Miki, and H. Shimokata Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese J. Hum. Genet. 48 2003 469 475
98. M. Rosenblat, D. Draganov, C.E. Watson, C.L. Bisgaier, B.N. La Du, and M. Aviram Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress Arterioscler. Thromb. Vasc. Biol. 23 2003 468 474
99. M. Rosenblat, T. Hayek, K. Hussein, and M. Aviram Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy Arterioscler. Thromb. Vasc. Biol. 24 2004 175 180
100. S. Campo, A.M. Sardo, G.M. Campo, A. Avenoso, M. Castaldo, A. D'Ascola, E. Giunta, A. Calatroni, and A. Saitta Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy Mutat. Res. 546 2004 75 80
101. B. Mackness, P.N. Durrington, and M.I. Mackness The paraoxonase gene family and coronary heart disease Curr. Opin. Lipidol. 13 2002 357 362
102. H.L. Li, D.P. Liu, and C.C. Liang Paraoxonase gene polymorphisms, oxidative stress, and diseases J. Mol. Med. 81 2003 766 779